The Computerised Design of Prestressed Cncrete Slabs

This thesis was aimed at the development of a finite element based software package for the analysis and design of prestressed concrete slabs. Many of the existing packages used in this area carry out a simplified two dimensional analysis of the slab which does not account for the secondary stresses set up by the presence of openings and notches in the slab. In an attempt to overcome this particular weakness, a finite element analysis package was written to help produce a more rigorous analysis of the stresses developed in prestressed concrete. The aims of the research were the examination of prestressed concrete theory, the identification of a suitable finite element model and the implementation of both theory and model through a purpose written software package. A combination of two finite element models, plate bending and plane stress, were used to simulate the effect of the axial stress imparted to the concrete by the strands and the moment applied to the section due to the eccentricity of the strands. The stresses encountered at transfer and during service conditions were examined in the software. Good programming practices such as minimised storage structures and the development of an efficient matrix solver were integral to the development of an effective software tool. Finally, the results produced by the software were examined and compared with those calculated using an established finite element analysis package. Ansys was chosen for this purpose as it has the flexibility to be applied to this particular package. The process of writing the software showed that an extensive amount of work was involved in debugging the code. An understanding was developed of the stages of evolution through which software of this type passes before completion. The software produced results that were broadly in line with those predicted by Anysys. However, the arduous task of setting up the model in Ansys showed that software tailored for use in the prestressed concrete field that would produce reasonably accurate results would have a place in industry

Effects of Accelerated Carbonation Curing on CO2 Sequestration and on the Compressive Strength of Concrete Masonry Units

The global consumption of Portland cement has risen to over 4 billion tonnes per annum. Its manufacture is energy and carbon intensive and approximately 900 kg of CO2 is emitted into the atmosphere for each tonne of Portland cement produced. The International Energy Agency (IEA) roadmap sets out a goal to reduce emissions due to cement production to 18 % below 2006 levels by 2050. Concrete has the potential to re-absorb CO2 by the process of carbonation, where it reacts with CaO in the concrete to form calcium carbonate. Accelerated carbonation curing (ACC) is a technique for curing fresh concrete that can sequester CO2. ACC of concrete masonry units (CMU’s) can reduce the embodied carbon footprint and play a major role in sustainability by reducing global CO2. ACC also offers potential improvements in the mechanical and durability properties of concrete. Experimental work was carried out which involved the ACC of CMU’s at a CO2 concentration of 50% over various time intervals and exposure conditions. It was calculated that the maximum possible CO2 uptake potential of the cement was approximately 49.5%. A CO2 uptake of 23% per mass of cement was achieved after 7 days of ACC along with compressive strength increases of 15.4% and 28% for ACC samples at 7 and 28 days respectively. The study found that the greatest compressive strength increase occurred between 4 and 24 hours. After 24 hours the ACC process showed a similar proportional rate of strength gain over time when compared to the control. The study shows that ACC is different from weathering carbonation as it accelerates the hydration reaction of the unhydrated cement phases C3S and C2S producing rapid strength gains. Weathering carbonation occurs in concrete after the hydration process has been predominately completed and results in the decalcification of C-S-H and the formation of silica gel which is detrimental to the cement paste

The use of three-dimensional conjugate CFD to enhance understanding of, and to verify, multi-modal heat transfer in dynamic laboratory test walls

This work describes the use of conjugate computational fluid dynamics (C-CFD) to simulate controlled laboratory based dynamic heat transfer tests on building components. This study proposes that conjugate CFD simulation can be used to evaluate the influence of combined convective and conductive heat transfer in multi-state building components. To this end, a solid wall and cavity wall were tested with a Calibrated Hotbox and subject to variable temperature conditions leading to combined convective and conductive heat transfer. The varying temperature of the heat source was monitored and used as the input boundary condition in the simulation model, which included a computational domain which encompassed the hot-side air chamber and the wall, including cavity when applicable. It was found acceptable accuracy could be realized with a simplified constant surface heat transfer coefficient with fixed air temperature on the cold air side, which greatly reduced computational effort. The experimental results revealed that the cavity wall experienced a phase lag, peak displacement of 2.9 times higher and decrement factor 1.6 times lower compared with that of the solid wall

Linking Geospatial Engineering into Collaborative Multidisciplinary BIM Projects - an Educational Perspective

This paper describes the background to and execution of a postgraduate project undertaken by students on DIT\u27s MSc in Geospatial Engineering (GeoEng) in support of a project on level 2 BIM being undertaken by students on the MSc in applied Building Information Modelling & Management (aBIMM) around the retrofit of and new build extension to the Grangegorman Clock Tower Building. In support of this requirement, an external and internal survey of the existing structure and its surrounding topography was required. The aBIMM students and staff acted as the Design Team who subcontracted the Geo Eng group who were organised into a survey team with a Topcon Ireland surveyor as team leader. Students and staff, at the end of the project, recognised the need for significant upskilling of both Geospatial and Design professionals around the different requirements, time-scales and costs, associated with surveying for BIM versus traditional survey deliverables. The experience of this project showed that these design teams would be prepared to pay for a more value-added product than the basic point cloud. The onus now is on Geospatial practitioners to take advantage of the opportunity afforded by collaborative BIM to engage early, often, and meaningfully in projects, and this will bring benefits to the geospatial profession as well as to the client, to the design team, and to the wider economy

Algorithmic governance: Developing a research agenda through the power of collective intelligence

We are living in an algorithmic age where mathematics and computer science are coming together in powerful new ways to influence, shape and guide our behaviour and the governance of our societies. As these algorithmic governance structures proliferate, it is vital that we ensure their effectiveness and legitimacy. That is, we need to ensure that they are an effective means for achieving a legitimate policy goal that are also procedurally fair, open and unbiased. But how can we ensure that algorithmic governance structures are both? This article shares the results of a collective intelligence workshop that addressed exactly this question. The workshop brought together a multidisciplinary group of scholars to consider (a) barriers to legitimate and effective algorithmic governance and (b) the research methods needed to address the nature and impact of specific barriers. An interactive management workshop technique was used to harness the collective intelligence of this multidisciplinary group. This method enabled participants to produce a framework and research agenda for those who are concerned about algorithmic governance. We outline this research agenda below, providing a detailed map of key research themes, questions and methods that our workshop felt ought to be pursued. This builds upon existing work on research agendas for critical algorithm studies in a unique way through the method of collective intelligence

Circulating microRNAs in sera correlate with soluble biomarkers of immune activation but do not predict mortality in ART treated individuals with HIV-1 infection: A case control study

Introduction: The use of anti-retroviral therapy (ART) has dramatically reduced HIV-1 associated morbidity and mortality. However, HIV-1 infected individuals have increased rates of morbidity and mortality compared to the non-HIV-1 infected population and this appears to be related to end-organ diseases collectively referred to as Serious Non-AIDS Events (SNAEs). Circulating miRNAs are reported as promising biomarkers for a number of human disease conditions including those that constitute SNAEs. Our study sought to investigate the potential of selected miRNAs in predicting mortality in HIV-1 infected ART treated individuals. Materials and Methods: A set of miRNAs was chosen based on published associations with human disease conditions that constitute SNAEs. This case: control study compared 126 cases (individuals who died whilst on therapy), and 247 matched controls (individuals who remained alive). Cases and controls were ART treated participants of two pivotal HIV-1 trials. The relative abundance of each miRNA in serum was measured, by RTqPCR. Associations with mortality (all-cause, cardiovascular and malignancy) were assessed by logistic regression analysis. Correlations between miRNAs and CD4+ T cell count, hs-CRP, IL-6 and D-dimer were also assessed. Results: None of the selected miRNAs was associated with all-cause, cardiovascular or malignancy mortality. The levels of three miRNAs (miRs -21, -122 and -200a) correlated with IL-6 while miR-21 also correlated with D-dimer. Additionally, the abundance of miRs -31, -150 and -223, correlated with baseline CD4+ T cell count while the same three miRNAs plus miR- 145 correlated with nadir CD4+ T cell count. Discussion: No associations with mortality were found with any circulating miRNA studied. These results cast doubt onto the effectiveness of circulating miRNA as early predictors of mortality or the major underlying diseases that contribute to mortality in participants treated for HIV-1 infection

Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial

Background Some high-income countries have deployed fourth doses of COVID-19 vaccines, but the clinical need, effectiveness, timing, and dose of a fourth dose remain uncertain. We aimed to investigate the safety, reactogenicity, and immunogenicity of fourth-dose boosters against COVID-19.Methods The COV-BOOST trial is a multicentre, blinded, phase 2, randomised controlled trial of seven COVID-19 vaccines given as third-dose boosters at 18 sites in the UK. This sub-study enrolled participants who had received BNT162b2 (Pfizer-BioNTech) as their third dose in COV-BOOST and randomly assigned them (1:1) to receive a fourth dose of either BNT162b2 (30 µg in 0·30 mL; full dose) or mRNA-1273 (Moderna; 50 µg in 0·25 mL; half dose) via intramuscular injection into the upper arm. The computer-generated randomisation list was created by the study statisticians with random block sizes of two or four. Participants and all study staff not delivering the vaccines were masked to treatment allocation. The coprimary outcomes were safety and reactogenicity, and immunogenicity (antispike protein IgG titres by ELISA and cellular immune response by ELISpot). We compared immunogenicity at 28 days after the third dose versus 14 days after the fourth dose and at day 0 versus day 14 relative to the fourth dose. Safety and reactogenicity were assessed in the per-protocol population, which comprised all participants who received a fourth-dose booster regardless of their SARS-CoV-2 serostatus. Immunogenicity was primarily analysed in a modified intention-to-treat population comprising seronegative participants who had received a fourth-dose booster and had available endpoint data. This trial is registered with ISRCTN, 73765130, and is ongoing.Findings Between Jan 11 and Jan 25, 2022, 166 participants were screened, randomly assigned, and received either full-dose BNT162b2 (n=83) or half-dose mRNA-1273 (n=83) as a fourth dose. The median age of these participants was 70·1 years (IQR 51·6–77·5) and 86 (52%) of 166 participants were female and 80 (48%) were male. The median interval between the third and fourth doses was 208·5 days (IQR 203·3–214·8). Pain was the most common local solicited adverse event and fatigue was the most common systemic solicited adverse event after BNT162b2 or mRNA-1273 booster doses. None of three serious adverse events reported after a fourth dose with BNT162b2 were related to the study vaccine. In the BNT162b2 group, geometric mean anti-spike protein IgG concentration at day 28 after the third dose was 23 325 ELISA laboratory units (ELU)/mL (95% CI 20 030–27 162), which increased to 37 460 ELU/mL (31 996–43 857) at day 14 after the fourth dose, representing a significant fold change (geometric mean 1·59, 95% CI 1·41–1·78). There was a significant increase in geometric mean anti-spike protein IgG concentration from 28 days after the third dose (25 317 ELU/mL, 95% CI 20 996–30 528) to 14 days after a fourth dose of mRNA-1273 (54 936 ELU/mL, 46 826–64 452), with a geometric mean fold change of 2·19 (1·90–2·52). The fold changes in anti-spike protein IgG titres from before (day 0) to after (day 14) the fourth dose were 12·19 (95% CI 10·37–14·32) and 15·90 (12·92–19·58) in the BNT162b2 and mRNA-1273 groups, respectively. T-cell responses were also boosted after the fourth dose (eg, the fold changes for the wild-type variant from before to after the fourth dose were 7·32 [95% CI 3·24–16·54] in the BNT162b2 group and 6·22 [3·90–9·92] in the mRNA-1273 group).Interpretation Fourth-dose COVID-19 mRNA booster vaccines are well tolerated and boost cellular and humoral immunity. Peak responses after the fourth dose were similar to, and possibly better than, peak responses after the third dose

Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D Study

Ristola M. on työryhmien DAD Study Grp ; Royal Free Hosp Clin Cohort ; INSIGHT Study Grp ; SMART Study Grp ; ESPRIT Study Grp jäsen.Background Chronic kidney disease (CKD) is a major health issue for HIV-positive individuals, associated with increased morbidity and mortality. Development and implementation of a risk score model for CKD would allow comparison of the risks and benefits of adding potentially nephrotoxic antiretrovirals to a treatment regimen and would identify those at greatest risk of CKD. The aims of this study were to develop a simple, externally validated, and widely applicable long-term risk score model for CKD in HIV-positive individuals that can guide decision making in clinical practice. Methods and Findings A total of 17,954 HIV-positive individuals from the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study with >= 3 estimated glomerular filtration rate (eGFR) values after 1 January 2004 were included. Baseline was defined as the first eGFR > 60 ml/min/1.73 m2 after 1 January 2004; individuals with exposure to tenofovir, atazanavir, atazanavir/ritonavir, lopinavir/ritonavir, other boosted protease inhibitors before baseline were excluded. CKD was defined as confirmed (>3 mo apart) eGFR In the D:A:D study, 641 individuals developed CKD during 103,185 person-years of follow-up (PYFU; incidence 6.2/1,000 PYFU, 95% CI 5.7-6.7; median follow-up 6.1 y, range 0.3-9.1 y). Older age, intravenous drug use, hepatitis C coinfection, lower baseline eGFR, female gender, lower CD4 count nadir, hypertension, diabetes, and cardiovascular disease (CVD) predicted CKD. The adjusted incidence rate ratios of these nine categorical variables were scaled and summed to create the risk score. The median risk score at baseline was -2 (interquartile range -4 to 2). There was a 1: 393 chance of developing CKD in the next 5 y in the low risk group (risk score = 5, 505 events), respectively. Number needed to harm (NNTH) at 5 y when starting unboosted atazanavir or lopinavir/ritonavir among those with a low risk score was 1,702 (95% CI 1,166-3,367); NNTH was 202 (95% CI 159-278) and 21 (95% CI 19-23), respectively, for those with a medium and high risk score. NNTH was 739 (95% CI 506-1462), 88 (95% CI 69-121), and 9 (95% CI 8-10) for those with a low, medium, and high risk score, respectively, starting tenofovir, atazanavir/ritonavir, or another boosted protease inhibitor. The Royal Free Hospital Clinic Cohort included 2,548 individuals, of whom 94 individuals developed CKD (3.7%) during 18,376 PYFU (median follow-up 7.4 y, range 0.3-12.7 y). Of 2,013 individuals included from the SMART/ESPRIT control arms, 32 individuals developed CKD (1.6%) during 8,452 PYFU (median follow-up 4.1 y, range 0.6-8.1 y). External validation showed that the risk score predicted well in these cohorts. Limitations of this study included limited data on race and no information on proteinuria. Conclusions Both traditional and HIV-related risk factors were predictive of CKD. These factors were used to develop a risk score for CKD in HIV infection, externally validated, that has direct clinical relevance for patients and clinicians to weigh the benefits of certain antiretrovirals against the risk of CKD and to identify those at greatest risk of CKD.Peer reviewe